We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 21, 2020

Lipoprotein(a) Lowering by Alirocumab and Total CV Events

European Heart Journal


Additional Info

Disclosure statements are available on the authors' profiles:

European Heart Journal
Lipoprotein(a) Lowering by Alirocumab Reduces the Total Burden of Cardiovascular Events Independent of Low-Density Lipoprotein Cholesterol Lowering: ODYSSEY OUTCOMES Trial
Eur Heart J 2020 Oct 14;[EPub Ahead of Print], M Szarek, VA Bittner, P Aylward, M Baccara-Dinet, DL Bhatt, R Diaz, Z Fras, SG Goodman, S Halvorsen, RA Harrington, JW Jukema, PM Moriarty, R Pordy, KK Ray, P Sinnaeve, S Tsimikas, R Vogel, HD White, D Zahger, AM Zeiher, PG Steg, GG Schwartz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading